Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant abiraterone plus radical prostatectomy in locally advanced prostate cancer
ChiCTR2600125584Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abiraterone in prostate adenocarcinoma, sponsored by Beijing Hospital. Primary endpoint: Biochemical recurrence-free survival time. Planned start May 2026; status: not yet recruiting.
02
Drugs
abiraterone
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600125584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125584.